U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/588,862-Conf. #4070	
INFORMATION DISCLOSURE				Filing Date	June 19, 2007	
S	STATEMENT BY APPLICANT			First Named Inventor	Nils Griebenow	
				Art Unit	1611	
(Use as many sheets as necessary)			s necessary)	Examiner Name	K. Klinkel	
Sheet	1	of	1	Attorney Docket Number	BHC 031071 [81927(303989)]	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA*	6,537,987	03-25-2003	Hamanaka et al.		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T^6

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	CA	G. Assmann et al.: "The Münster Heart Study (PROCAM)," European Heart Journal, Vol. 19, Supp. A., 1998, pp. A2-A11			
	СВ	N. S. Watson et al.: "7 Squalene Synthase Inhibitors: Their Potential as Hypocholesterolaemic Agents," Progress in Medicinal Chemistry, Vol. 33, 1996, pp. 331-378			
	СС	H. Hiyoshi et al.: "Squalene Synthase Inhibitors Reduce Plasma Triglyceride Through a Low- Density Lipoprotein Receptor-Independent Mechanism," European Journal of Pharmacology, Vol. 431, 2001, pp. 345-352			
	CD	S. L. Morissette et al.: "High-throughput Crystallization: Polymorphs, Salts, Co-crystals and Solvates of Pharmaceutical Solids," Advanced Drug Delivery Reviews, Vol. 56, 2004, pp. 275-300			
	CE	S. R. Vippagunta et al.: "Crystalline Solids," Advanced Drug Delivery Reviews, Vol. 48, 2001, pp. 3-26			
	CF	J Pandit et al.: "Crystal Structure of Human Squalene Synthase," The Journal of Biological Chemistry, Vol. 275, No. 39, 2000, pp.30610-30617			

Examiner	Date	
Signature	Considered	

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: September 11, 2009 Electronic Signature for Gabriel J. McCool: /Gabriel J. McCool/

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.